"Cardiotonic Agents" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Agents that have a strengthening effect on the heart or that can increase cardiac output. They may be CARDIAC GLYCOSIDES; SYMPATHOMIMETICS; or other drugs. They are used after MYOCARDIAL INFARCT; CARDIAC SURGICAL PROCEDURES; in SHOCK; or in congestive heart failure (HEART FAILURE).
Descriptor ID |
D002316
|
MeSH Number(s) |
D27.505.954.411.222 D27.720.799.080
|
Concept/Terms |
Cardiotonic Agents- Cardiotonic Agents
- Cardiac Stimulants
- Inotropic Agents, Positive Cardiac
- Cardiotonic Drugs
- Cardiotonics
- Myocardial Stimulants
- Cardioprotective Agents
|
Below are MeSH descriptors whose meaning is more general than "Cardiotonic Agents".
Below are MeSH descriptors whose meaning is more specific than "Cardiotonic Agents".
This graph shows the total number of publications written about "Cardiotonic Agents" by people in this website by year, and whether "Cardiotonic Agents" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
Year | Major Topic | Minor Topic | Total |
---|
2003 | 1 | 0 | 1 |
2013 | 2 | 1 | 3 |
2014 | 1 | 1 | 2 |
2015 | 0 | 1 | 1 |
2016 | 1 | 1 | 2 |
2018 | 0 | 1 | 1 |
2020 | 0 | 2 | 2 |
To return to the timeline,
click here.
Below are the most recent publications written about "Cardiotonic Agents" by people in Profiles.
-
Sacubitril/Valsartan in Advanced Heart Failure With Reduced Ejection Fraction: Rationale and Design of the LIFE Trial. JACC Heart Fail. 2020 10; 8(10):789-799.
-
Growing Mismatch Between Evidence Generation and Implementation in Heart Failure. Am J Med. 2020 05; 133(5):525-527.
-
Prevalent digoxin use and subsequent risk of death or hospitalization in ambulatory heart failure patients with a reduced ejection fraction-Findings from the Heart Failure: A Controlled Trial Investigating Outcomes of Exercise Training (HF-ACTION) randomized controlled trial. Am Heart J. 2018 05; 199:97-104.
-
Early inpatient calculation of laboratory-based 30-day readmission risk scores empowers clinical risk modification during index hospitalization. Am Heart J. 2017 Mar; 185:101-109.
-
Digoxin for Worsening Chronic Heart Failure: Underutilized and Underrated. JACC Heart Fail. 2016 05; 4(5):365-7.
-
Reporting on the Strategies Needed to Implement Proven Interventions: An Example From a "Real-World" Cross-Setting Implementation Study. Mayo Clin Proc. 2016 Aug; 91(8):1074-83.
-
Patterns of intensive care unit admissions in patients hospitalized for heart failure: insights from the RO-AHFS registry. J Cardiovasc Med (Hagerstown). 2015 May; 16(5):331-40.
-
The use of digoxin in patients with worsening chronic heart failure: reconsidering an old drug to reduce hospital admissions. J Am Coll Cardiol. 2014 May 13; 63(18):1823-32.
-
The global health and economic burden of hospitalizations for heart failure: lessons learned from hospitalized heart failure registries. J Am Coll Cardiol. 2014 Apr 01; 63(12):1123-1133.
-
Effectiveness and safety of digoxin among contemporary adults with incident systolic heart failure. Circ Cardiovasc Qual Outcomes. 2013 Sep 01; 6(5):525-33.